Helmut Gadner

Active 1977–2021

113
Papers
24,179
Citations
94
h-index
113
i10-index

Citations

Citations per year for Helmut Gadner1978: 1 citations1980: 1 citations1984: 4 citations1985: 5 citations1986: 6 citations1987: 3 citations1988: 5 citations1989: 2 citations1990: 6 citations1991: 19 citations1992: 5 citations1993: 12 citations1994: 37 citations1995: 34 citations1996: 45 citations1997: 28 citations1998: 73 citations1999: 77 citations2000: 121 citations2001: 111 citations2002: 145 citations2003: 173 citations2004: 170 citations2005: 217 citations2006: 185 citations2007: 171 citations2008: 240 citations2009: 237 citations2010: 236 citations2011: 179 citations2012: 201 citations2013: 140 citations2014: 156 citations2015: 178 citations2016: 111 citations2017: 113 citations2018: 104 citations2019: 300 citations2020: 354 citations2021: 283 citations2022: 184 citations2023: 145 citations2024: 228 citations2025: 87 citations1979: no citations, so this year is not shown1981–1983: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,611 citing papers, 23.7% of this breakdownGermany: 683 citing papers, 10% of this breakdownItaly: 426 citing papers, 6.3% of this breakdownUnited Kingdom: 407 citing papers, 6% of this breakdownFrance: 360 citing papers, 5.3% of this breakdownNetherlands: 323 citing papers, 4.7% of this breakdownAustria: 322 citing papers, 4.7% of this breakdownChina: 280 citing papers, 4.1% of this breakdownCanada: 238 citing papers, 3.5% of this breakdownSweden: 190 citing papers, 2.8% of this breakdownSwitzerland: 184 citing papers, 2.7% of this breakdownJapan: 162 citing papers, 2.4% of this breakdown
0%23.7%Other 23.8%

Fields

  • Medicine85.5%
  • Biochemistry, Genetics and Molecular Biology9.8%
  • Immunology and Microbiology3.3%
  • Engineering0.4%
  • Materials Science0.2%
  • Neuroscience0.2%
  • Other0.6%

Topics

  • Acute Lymphoblastic Leukemia research10%
  • Sarcoma Diagnosis and Treatment7.3%
  • Childhood Cancer Survivors' Quality of Life5.3%
  • Acute Myeloid Leukemia Research5.1%
  • Lymphoma Diagnosis and Treatment3.7%
  • Autoimmune and Inflammatory Disorders Research3.4%
  • Other65.2%

Coauthors

All papers

Open in search
  1. Primary Metastatic Osteosarcoma: Presentation and Outcome of Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols

    Authors: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2003 cited by 957

  2. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol

    Authors: , , , , , , , , , , , - Blood 2011 cited by 677

  3. Prognostic Factors in Ewing’s Tumor of Bone: Analysis of 975 Patients From the European Intergroup Cooperative Ewing’s Sarcoma Study Group

    Authors: , , , , , , - Journal of Clinical Oncology 2000 cited by 1,045

  4. HLH-94: A treatment protocol for hemophagocytic lymphohistiocytosis

    Authors: , , , , , , , , , , , - Medical and Pediatric Oncology 1997 cited by 535

  5. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis

    Authors: , , , , , , , , , , , , , , - Blood 2013 cited by 450

  6. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2008 cited by 610

  7. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2011 cited by 438

  8. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000

    Authors: , , , , , , , , , , , , , , , , , , , , - Leukemia 2009 cited by 521

  9. Prednisone Response Is the Strongest Predictor of Treatment Outcome in Infant Acute Lymphoblastic Leukemia

    Authors: , , , , , , , , - Blood 1999 cited by 346

  10. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients?

    Authors: , , , , , , , , , - Journal of Clinical Oncology 1996 cited by 322

  11. Results of Treatment for Soft Tissue Sarcoma in Childhood and Adolescence: A Final Report of the German Cooperative Soft Tissue Sarcoma Study CWS-86

    Authors: , , , , , , , , , , - Journal of Clinical Oncology 1999 cited by 270

  12. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy

    Authors: , , , , , , , , , , - Blood 2008 cited by 153

  13. Contemporary classification of histiocytic disorders

    Authors: , , , , , , , , , , , , , , , , , - Medical and Pediatric Oncology 1997 cited by 838

  14. MIC2 is a specific marker for ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration

    Authors: , , , , , - Cancer 1991 cited by 657

  15. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995

    Authors: , , , , , , , , - Leukemia 2000 cited by 530

  16. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification

    Authors: , , , , , , , , , , - Blood 2007 cited by 332

  17. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Martin Schrappe - Leukemia 2003 cited by 239

  18. Cooperative Trial CWS-91 for Localized Soft Tissue Sarcoma in Children, Adolescents, and Young Adults

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2009 cited by 177

  19. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible

    Authors: , , , , , , , , , , , , , - Cytometry Part B Clinical Cytometry 2008 cited by 156

  20. Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: Report of the HD CWS‐96 trial

    Authors: , , , , , , , , , , - Pediatric Blood & Cancer 2008 cited by 127

  21. Localized Ewing Tumor of Bone: Final Results of the Cooperative Ewing’s Sarcoma Study CESS 86

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2001 cited by 443

  22. Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis

    Authors: , , , , , , , , , , , - British Journal of Haematology 2007 cited by 264

  23. Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis

    Authors: , , , , , , , , , , , , - British Journal of Haematology 2005 cited by 235

  24. Skip Metastases in Osteosarcoma: Experience of the Cooperative Osteosarcoma Study Group

    Authors: , , , , , , , , , , , , - Journal of Clinical Oncology 2006 cited by 142